Giovannoni G, Rammohan K, Cook S, et al. Proportions of patients with highly active RMS achieving no evidence of disease activity (NEDA) in response to cladribine tablets in CLARITY. ECTRIMS 217, P1143.
Solanezumab bij preklinische ziekte van Alzheimer: fase III-resultaten
okt 2023 | Dementie